• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hum Vaccin Immunother . RSV-related hospital admissions in a subset of hospitals in England and Scotland: A real-world study (2018-2023)

tetano

Editor, Senior Moderator
Hum Vaccin Immunother


. 2026 Dec;22(1):2675075.
doi: 10.1080/21645515.2026.2675075. Epub 2026 Jul 10.
RSV-related hospital admissions in a subset of hospitals in England and Scotland: A real-world study (2018-2023)

Rachel M Reeves[SUP] 1 [/SUP], Shammi Luhar[SUP] 2 [/SUP], Triantafyllos Pliakas[SUP] 3 4 [/SUP], Emily Phipps[SUP] 5 [/SUP], Danielle E Robinson[SUP] 2 [/SUP], Alycia Perkins[SUP] 2 [/SUP], Jamie Wallis[SUP] 2 [/SUP], Lewis Carpenter[SUP] 2 [/SUP], Elisa Turriani[SUP] 6 [/SUP], Alen Marijam[SUP] 7 [/SUP]


Affiliations
Abstract

Respiratory syncytial virus (RSV) is a major cause of acute respiratory infection (ARI), though its healthcare burden and costs are insufficiently described among adults in the United Kingdom. With the recent availability of vaccines, understanding RSV-related secondary care burden is essential. Routinely collected adult ARI hospitalization data between 2018 and 2023 from four English National Health Service (NHS) trusts and a Scottish Health Board were linked to RSV, influenza, and coronavirus disease 2019 (COVID-19) microbiology tests and results. ARI incidence risk and ARI-related hospitalizations overall and per pathogen were described (including mortality, hospitalization length of stay [LoS], intensive care unit [ICU] admissions/LoS, and costs). RSV-positive microbiology tests and International Classification of Diseases (ICD)-10 RSV diagnoses were compared. In both settings, incidence risk of first ARI hospitalizations increased from 2018/19 to 2022/23. Of RSV-tested hospitalizations, 7.0% (England) and 4.1% (Scotland) had an RSV-positive test. Of these, 7.4% and 8.0% died in hospital, respectively; similar proportions were observed for influenza (5.5% and 5.0%). In England and Scotland, RSV-positive hospitalization LoS was 5 and 6 d, comparable to COVID-19 (8 and 10) and influenza (4 and 3). ICU admittance and direct costs per hospitalization were generally comparable across pathogens. In England and Scotland, 63.5% and 33.7% of RSV-positive hospitalizations had an RSV ICD-10 code, respectively. Among English and Scottish adults, RSV-positive hospitalizations had substantial healthcare resource utilization, comparable to COVID-19- and influenza-positive hospitalizations. ICD-10 codes are limited proxies for identifying RSV hospitalizations. Broadening RSV adult vaccination recommendations may reduce the RSV secondary care burden.

Keywords: COVID-19; Respiratory syncytial virus; acute respiratory infection; burden of disease; hospital admission; influenza.

 
Back
Top